Many adaptations to the coronavirus pandemic will remain standard features of health care long after the pandemic wanes, according to Brian Chapman, managing partner at ZS Associates, an Evanston, Ill.-based pharmaceutical and medical technology consultancy. In the long term, telehealth will be a clear winner as payers look to lower ongoing costs, more procedures and care will move out of hospitals, rapid diagnostics will gain importance, and government and payer coverage of infectious disease testing of all kinds will expand, he predicted.

An artificial intelligence-based system can accurately detect COVID-19 using thoracic CT scans in patients with respiratory symptoms, according to a preprint study published on arXiv.org. The system can also help monitor patients with the disease. Other teams have employed AI to speed diagnosis and develop clarity on the signature appearance of the disease in the lungs of symptomatic patients.

Erlangen, Germany-based Siemens Healthineers AG has secured U.S. FDA clearance for its Rapidpoint 500e blood gas analyzer. Available in CE mark countries since August 2019, the device is used to monitor respiratory distress in critically ill patients, such as those in acute care due to COVID-19.

Systematic detection of cancer at earlier stages at a population level could remodel how the medical profession approaches cancer treatment, establishing the potential to reduce cancer mortality by almost one-quarter. That’s according to an analysis based on the latest data from Grail Inc.'s Circulating Cell-free Genome Atlas (CCGA) study.

PARIS – Europe has turned into the epicenter of the coronavirus pandemic, seeing more than 50% of the cases observed worldwide. In fact, whereas the COVID-19 pandemic has begun declining in China where it originated, there are 400,000 cases of coronavirus worldwide, including more than 200,000 infected by SARS-CoV-2 in the 55 sovereign states in continental Europe, where they are mourning more than 18,000 deaths.

Disaster Management Group (DMG), of Indiantown, Fla., has launched a 15-minute screening tool for COVID-19 that can be administered at drive-thru testing sites. The DMGtest, which is being offered under an FDA waiver, first rolled out in Florida and will soon be available in other parts of the U.S.

Leuven, Belgium-based Midiagnostics NV, which is looking to bring miniaturized, rapid, blood-based tests with built-in connectivity to both patients and clinicians, reported the completion of a €14 million (US$15.4 million) investment round. The company intends to use the funds to speed the development of its nanofluidic processor on a chip and prepare it for industrial-scale manufacturing.